CD8A and neoplasm: For example, Cooper et al. reported that the administration of BRAF inhibitors increases the CD8+ T cells among tumor-infiltrating lymphocytes (TILs) and decreases immunosuppressive cytokines, leading to suppression of growth of BRAF (V600E)/PTEN−/− melanoma in vivo [34].